Access hFSH 33520Recalls & reported problems
Beckman Coulter, Inc. · The Access hFSH assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of follicle stimulating hormone (FSH) levels in human serum and plasma using the Access Immunoassay Systems. · Class 1
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 1
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 15099590575236), received between Apr 17, 2019 and Apr 17, 2019 — classified as 1 injury.
The most frequently reported specific device problem is “High Test Results” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.
Most reported problems
Device problems
- High Test Results1
Patient problems
- No Code Available1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
InjuryApr 17, 2019High Test Results; High Test Results
THE CUSTOMER CONTACTED BECKMAN COULTER (BCI) TO REPORT OBTAINING A HIGHER THAN EXPECTED FOLLICLE STIMULATING HORMONE (ACCESS HFSH) RESULT FOR ONE FEMALE PATIENT ON THE LABORATORY¿S ACCESS 2 IMMUNOASSAY ANALYZER SERIAL NUMBER (B)(4). THE FIRST ACCESS HFSH RESULT QUESTIONED WAS ON (B)(6) 2019. THE CUSTOMER TOOK THE PATIENT OFF OF THEIR BIRTH-CONTROL MEDICATION AT THIS TIME. ANOTHER SAMPLE WAS COLLECTED AND TESTED FOR ACCESS HFSH AGAIN; ANOTHER HIGHER THAN EXPECTED RESULT WAS OBTAINED. THE CUSTOMER PERFORMED LINEAR DILUTIONS AND NOTED THAT THE RESULTS OBTAINED WERE NOT LINEAR SUGGESTING THAT A PATIENT-SOURCE INTERFERENT WAS PRESENT. THE PATIENT THEN HAD AN MRI (MAGNETIC RESONANCE IMAGING) OF THE HEAD PERFORMED WHICH WAS NORMAL (IT IS UNKNOWN IF CONTRAST DYE WAS USED). IN ADDITION, THE PATIENT RECEIVED TREATMENT WITH A GNRH (GONADOTROPIN-RELEASING HORMONE) ANTAGONIST, HOWEVER, THE ACCESS HFSH RESULT WAS STILL HIGHER THAN EXPECTED. ON (B)(6) 2019 A THIRD SAMPLE WAS TESTED FOR THE ACCESS HFSH ASSAY AND THE RESULT WAS SIMILAR; STILL ELEVATED. THIS SAMPLE WAS ALSO SENT TO A REFERENCE LABORATORY WHICH USED A DIFFERENT METHODOLOGY (TYPE UNKNOWN) AND PRETREATMENT WITH A BLOCKING REAGENT. THE
Patient problems: No Code Available
MAUDE report 8524260 ↗
Other Radioimmunoassay, Follicle-Stimulating Hormone devices
- VIDAS® FSH 30407-01Biomerieux SA · RADIOIMMUNOASSAY, FOLLICLE-STIMULATING HORMONE1 recall0 reports
- VITROS 1931922Ortho Clinical Diagnostics · RADIOIMMUNOASSAY, FOLLICLE-STIMULATING HORMONE1 recall0 reports
- Elecsys FSH 08932352190Roche Diagnostics GmbH · RADIOIMMUNOASSAY, FOLLICLE-STIMULATING HORMONE4 reports
- Elecsys FSH 11775863122Roche Diagnostics GmbH · RADIOIMMUNOASSAY, FOLLICLE-STIMULATING HORMONE2 reports
- Elecsys FSH 08932387190Roche Diagnostics GmbH · RADIOIMMUNOASSAY, FOLLICLE-STIMULATING HORMONE1 report
Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.